Tarhini, A. (2013). Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica, 2013, 857519.
RESOURCE TYPE: Expert opinion
PHASE OF CARE: Active antitumor treatment
N/A
Expert opinion level evidence only
Patients receiving immunotherapy need to be monitored for immune-related adverse events, and quickly managed appropriately to prevent more severe complications. In addition, nurses should be aware of potential side effects of systemic steroid therapy if initiated.